|Mr. Thomas B. Neff||Founder, Chairman & CEO||1.75M||20.39M||1954|
|Mr. Pat Cotroneo||Sr. VP of Fin. & CFO||782.94k||6.35M||1964|
|Dr. K. Peony Yu||Chief Medical Officer||954.55k||1.12M||1962|
|Dr. Barry A. Berkowitz||Founder||N/A||N/A||N/A|
|Dr. Michael J. Martinelli||Sr. VP of Technical Devel.||N/A||N/A||N/A|
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 7.